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Abstract
Background and Objectives GSK2982772 is an oral small-molecule RIPK1 inhibitor with potential therapeutic efficacy 
in immune-mediated inflammatory diseases (IMIDs). An inter-ethnic comparison of GSK2982772 pharmacokinetics was 
conducted based on data from Western (Study 1) and Japanese subjects (Study 2).
Methods Both studies were single-centre, randomised, double-blind, placebo-controlled studies with objectives to assess 
the safety and characterise the pharmacokinetics of GSK2982772. Western subjects in Study 1 (NCT03305419), Part A 
(N = 15), were randomly assigned to receive 120 mg three times daily (TID), 240 mg TID, or 360 mg twice daily (BID) doses 
of GSK2982772, or placebo (TID or BID) for 1 day. Part B subjects (N = 47) received GSK2982772 120 mg TID, 240 mg 
TID, or placebo TID for 14 days. Japanese subjects in Study 2 (N = 13) (NCT03590613) were randomly assigned to receive 
TID doses of GSK2982772 60, 120, 240 mg TID or placebo TID for 1 day.
Results GSK2982772 was well tolerated and adverse events were generally mild. Maximum observed plasma drug concentra-
tion (Cmax), time to reach Cmax (Tmax), area under the plasma drug concentration versus time curve after the first GSK2982772 
dose (AUC (0–7)) of 120 and 240 mg, and (AUC (0–24)) values for the 120 and 240 mg TID doses over a single day were similar 
in Japanese and Western subjects.
Conclusions The pharmacokinetics and tolerability of GSK2982772 were similar between Western and Japanese subjects, 
justifying inclusion of Japanese subjects in future global clinical studies to assess the therapeutic potential of RIPK1 inhibi-
tion for the treatment of IMIDs.
Clinical Trials: NCT03305419 and NCT03590613 available from http://www.clini caltr ials.gov.
Key Points 
TID and BID dosing up to 720 mg daily of GSK2982772 
was well tolerated in Western and Japanese subjects.
Similar pharmacokinetics and tolerability of 
GSK2982772 between Western and Japanese subjects 
support inclusion of Japanese subjects in future global 
studies.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1331 8-020-00652 -2) contains 
supplementary material, which is available to authorized users.
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1 Introduction
GSK2982772 binds selectively to an allosteric pocket of 
the receptor-interacting protein kinase 1 (RIPK1) domain 
to inhibit RIPK1-mediated programmed cell death path-
ways and pro-inflammatory cytokine production [1]. 
Inhibitors of RIPK1 can modulate necroptosis, a form 
of programmed cell death that may play a role in the 
pathogenesis of immune-mediated inflammatory diseases 
(IMIDs), and thus GSK2982772 has emerged as a potential 
treatment for IMIDs such as psoriasis, rheumatoid arthri-
tis, and inflammatory bowel disease [1–3].
Following oral administration of GSK2982772 as 
powder in a capsule or a tablet, GSK2982772 was rap-
idly absorbed with a median time to maximum observed 
plasma concentration (Cmax) of 1.5–2.5  h post-dose. 
Approximate linear kinetics were displayed over the dose 
range of 0.1–120 mg and food had no significant impact 
on the rate or extent of absorption [1]. The majority of 
systemic exposure to GSK2982772 was associated with a 
half-life of 2–3 h. Consequently, initial experimental medi-
cine studies conducted with GSK2982772 for plaque-type 
psoriasis, rheumatoid arthritis, and ulcerative colitis used 
twice daily (BID) and three time a day (TID) dosage regi-
mens [4].
Following single-day and repeat dosing (120 mg BID) 
over 14  days, the principal components in blood and 
plasma were unchanged GSK2982772 and an N-glucuron-
ide metabolite (M8; GSK3562183) [1]. A minor desmethyl 
metabolite (M9; GSK2997852) was also present in plasma. 
In vitro studies indicate that UGT1A9 was the predomi-
nant enzyme catalysing the formation of M8 with minor 
contributions from UGT1A1 and UGT1A7.
This current analysis compares the pharmacokinetics 
and safety of GSK2982772 in healthy Western (predomi-
nantly White/European) subjects (Study 1) and Japanese 
subjects (Study 2). The main objectives of the Western 
study were to determine the pharmacokinetics and safety 
of GSK2982772 at higher single-day (120 mg TID, 240 mg 
TID, and 360 mg BID) and 14 day repeat doses (120 and 
240 mg TID) than studied previously in initial experi-
mental medicine studies (60 mg TID and 120 mg BID). 
The objective of the Japanese study was to determine the 
safety, tolerability, and pharmacokinetics of GSK2982772 
at doses up to 240 mg TID for a single day to support the 
inclusion of Japanese subjects in global phase 2b clinical 
trials and to explore the potential for inter-ethnic differ-
ences in the pharmacokinetics of GSK2982772.
Although the overall designs of the two studies were 
not the same, both studies included a single-day admin-
istration of 120 mg TID and 240 mg TID, which allowed 
for comparisons of pharmacokinetics in healthy Japanese 
and Western subjects. GSK2982772 was administered 
as tablets in the Japanese study and as capsules in the 
Western study. Both formulations of GSK2982772 have a 
similar rate and extent of absorption [1]. In vitro human 
hepatocyte studies with GSK2982772 indicated a moder-
ate potential for induction of cytochrome P450 enzymes 
at clinical doses of 240 mg TID. Therefore, in Study 1 
the plasma 4β-hydroxycholesterol-to-cholesterol ratio was 
measured as a biomarker of CYP3A4 activity [5].
2  Methods
2.1  Study Design
Study 1 (NCT03305419; initiated October 11, 2017, and 
completed October 15, 2018, at a single centre in the UK) 
was a randomised, double-blind (excluding the site phar-
macist), placebo-controlled study divided into two parts 
(Fig.  1). In Part A, subjects (cohort 1) were randomly 
assigned in a three-way crossover design to receive ascend-
ing doses of GSK2982772 120 mg TID, 240 mg TID, or 
360 mg BID for 1 day. In Part B, subjects received repeat 
doses of GSK2982772 120 mg TID in cohorts 2 and 3 and 
240 mg TID in cohort 4 for 14 days in a sequential group 
design.
In cohorts 1 and 2, subjects were randomised 3:1 to 
receive either GSK2982772 or placebo. However, due to an 
unexpectedly high number of asymptomatic arrhythmias, 
the study was paused after cohort 2. The ratio of subjects on 
active treatment versus placebo changed in cohorts 3 and 4 
to 9:5 to more closely monitor the effects of GSK2982772 
relative to placebo, including the 120 mg TID dose. A fifth 
cohort was planned (360 mg BID) but was not initiated 
as one subject at the 360 mg BID dose level in cohort 1 
exceeded the predefined Cmax stopping criteria.
For TID dosing in both parts of Study 1, GSK2982772 
or placebo was administered at 0, 7, and 14 h, with the first 
dose administered following an overnight fast. The 360 mg 
BID doses in Part A were administered at 0 and 12 h. The 
impact of food on steady-state GSK2982772 pharmacoki-
netic parameters was evaluated during the repeat dose phase 
in Part B. GSK2982772 was administered 30 min after a 
standard breakfast on Day 9 or after a high-fat breakfast on 
Day 11, and in the fasted state on Day 14, with the content of 
each breakfast aligned to US FDA recommendations [6]. On 
fasting days, breakfast was served approximately 2 h after 
dosing, and on all study days, lunch and dinner were served 
2–3 h prior to doses 2 and 3, respectively.
Study 2 (NCT03590613; initiated July 19, 2018, and 
completed September 26, 2018) was a single-centre, ran-
domised, double-blind, placebo-controlled study con-
ducted in Japan (Fig. 1). Subjects were randomly assigned 
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1:1:1:1 in a four-way crossover design to receive ascend-
ing doses of GSK2982772 60  mg TID, 120  mg TID, 
240 mg TID, and placebo TID for 1 day, using the same 
TID dosing interval as Study 1.
In Study 1, GSK2982772 was administered in capsule 
formulation. In Study 2, GSK2982772 was administered 
as a tablet formulation [1]. In both studies, placebo was 
matched in appearance to the active study drug. For each 
study, approval was obtained from the ethics committee 
of the clinical trial unit and each was conducted according 
to the recommendations of Good Clinical Practice and the 
Declaration of Helsinki (2013). Written informed consent 
was obtained from each subject prior to any study-related 
activities.
2.2  Subjects
Healthy male and female subjects aged 18–65  years, 
≥ 50 kg, and body mass index (BMI) 19–30 kg/m2 were eli-
gible for Study 1. The inclusion criteria for Study 2 included 
healthy male Japanese subjects, aged 20–64 years, ≥ 50 kg, 
and BMI 18.5–24.9  kg/m2. Full eligibility criteria are 
included in Supplemental Table 1.
2.3  Endpoints
Primary endpoints of both studies were the safety and tol-
erability of GSK2982772 (see Sect. 2.4).
The secondary endpoints for both studies were 
GSK2982772 pharmacokinetic parameters. In Study 
1, Part B, the impact of repeat dosing of GSK2982772 
for 14  days and the impact of co-administration of 
GSK2982772 with a standard and high-fat meal were 
determined.
The derived pharmacokinetic parameters were maxi-
mum observed plasma concentration (Cmax) and time to 
Cmax (Tmax) following each dose, area under the plasma drug 
concentration versus time curve over 24 h (AUC (0–24)) and 
over each dose interval (AUC (0–7), AUC (7–14), and AUC (14–24) 
for TID dosing and AUC (0–12) and AUC (12–24) for BID dos-
ing). Observed trough plasma drug concentrations were also 
assessed in both studies. The (t½) following the third dose 
was assessed in Japanese participants only.
Study 1 explored more than two main endpoints of safety 
and pharmacokinetics. In Study 1, Part B, the potential 
effect of repeat doses of GSK2982772 on CYP3A4 enzyme 
activity was assessed by comparing the ratio of plasma 
4β-hydroxycholesterol to cholesterol on Day 15 versus Day 1.
Study 1
Part A, Single-day GSK2982772 Ascending Dosesa
Group N  1 Day 1 Day 1 Day
Cohort 1
A 3 120 mg TID 240 mg TID 360 mg BID 
B 3 120 mg TID 240 mg TID Placebo
C 3 120 mg TID Placebo 360 mg BID
D 3 Placebo 240 mg TID 360 mg BID
Part B, Repeat GSK2982772 Dosesb
N 14 Days
Cohort 2 9 120 mg TID3 Placebo
Cohort 3 95 Placebo
Cohort 4 95 Placebo
Study 2 Single Daya
Group N 1 Day 1 Day 1 Day 1 Day
A 3 Placebo TID 60 mg TID 120 mg TID 240 mg TID
B 3 60 mg TID Placebo TID 120 mg TID 240 mg TID
C 3 60 mg TID 120 mg TID Placebo TID 240 mg TID
D 3 60 mg TID 120 mg TID 240 mg TID Placebo TID
120 mg TID
240 mg TID
Fig. 1  Design of the Western (Study 1) and Japanese (Study 2) stud-
ies. A fifth cohort (360 mg BID) was planned in Study 1 but was not 
conducted because one subject in cohort 1 exceeded the Cmax stop-
ping criteria at the 360 mg BID dose level. aA 7-day washout period 
was required between each single-day dosing period in Study 1, Part 
A, and Study 2. bEach cohort in Part B included different subjects. 
BID twice daily, Cmax maximum blood/plasma concentration, TID 
three times daily
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2.4  Safety Assessments and Tolerability
Safety and tolerability assessments included monitoring of 
adverse events (AEs), clinical laboratory values, vital signs 
(heart rate, blood pressure, and body temperature), elec-
trocardiogram, and physical examination. AEs and serious 
AEs (SAEs) were collected from the start of study treatment 
through the follow-up visit.
Assessment of the AEs/SAEs included evaluation of 
intensity as ‘mild’, ‘moderate’, or ‘severe’ as assessed by 
the investigator. All AEs/SAEs were followed by the inves-
tigator until resolution/stabilisation. AE and SAE reporting 
was performed according to the GCP Guidelines and the 
National regulatory authorities’ guidelines of the countries 
where the two studies were performed.
2.5  Blood Sampling
For the TID dosing regimen, blood samples were collected 
pre-dose, 20 min, 40 min, 1, 1.5, 2, 3, and 5 h following 
each dose of the single-day study period. For BID dosing, 
samples were collected pre-dose, 20 min, 40 min, 1, 1.5, 2, 
3, 4, 6, and 10 h after each dose. For TID dosing, pre-dose 
samples were taken just prior to the 7- and 14-h doses. For 
BID dosing, a pre-dose sample was taken just prior to the 
12-h dose. The pharmacokinetic blood sampling schedule 
for Part B of Study 1 is shown in Supplemental Table 2. On 
Days 2, 3, 4, 5, and 7, only pre-dose samples were obtained. 
On Day 14, blood sampling over 24 h was the same as the 
schedule for Part A. At all time points, 2 ml of whole blood 
samples was collected into K3 EDTA tubes.
2.6  Drug Assay
GSK2982772 plasma concentrations were measured for 
Study 1 at GSK, Ware, UK, and for Study 2 the assay was 
performed by Covance Laboratories (Harrogate, UK). For 
Study 1, the lower (LLQ) and higher (HLQ) limits of quan-
tification for GSK2982772 were 5 ng/ml and 5000 ng/ml 
using a 50 µl aliquot of human plasma. For Study 2, there 
was a low (LLQ and HLQ of 0.2 ng/ml and 200 ng/ml) and 
a high (LLQ and HLQ of 1 ng/ml and 1000 ng/ml) concen-
tration range method using a 30 µl aliquot (low) and a 25 µl 
aliquot (high) of human plasma.
For both assays, human plasma samples were ana-
lysed for GSK2982772 concentrations using a validated 
method (according to GSK standard operating procedures 
and bioanalytical method validation guidelines from the 
FDA and EMA) [7, 8] based on protein precipitation, fol-
lowed by HPLC/MS/MS analysis equipped with API5500 
(GSK) and API4000 (Covance) manufactured by Sciex, 
Framingham, MA, USA. GSK2982772 was extracted from 
human plasma via protein precipitation with acetonitrile 
containing an isotopically labelled internal standard,  [2H3 
13C]-GSK2982772.
Chromatography was completed on a C18 BEH column 
(50 × 2.1 mm, 1.7 μM, Waters, Milford, MA, USA) under 
linear gradient conditions; the mobile phases were (A) 
water containing 0.1% (v/v) formic acid and (B) acetoni-
trile. Quantitation was completed using multiple reaction 
monitoring (MRM) in positive mode producing transitions 
for GSK2982772 (m/z 378/204 (GSK) and m/z 378/255 
(Covance) and  [2H3 13C]-GSK2982772 (m/z 382/255). The 
intra- and inter-assay bias and precision were < 15%.
Quality control (QC) samples containing GSK2982772 at 
three different concentrations for Study 1 and four different 
concentrations for Study 2 were stored with study samples 
and analysed with each batch of samples against calibration 
standards. No more than one-third of the QC results were to 
deviate from the nominal concentration by more than 15%, 
and at least 50% of the results from each QC concentration 
should be within 15% of nominal.
2.7  Pharmacokinetic Analysis
Pharmacokinetic parameters were determined from plasma 
GSK2982772 concentration-time data using a standard non-
compartmental analysis with Phoenix WinNonlin version 
6.3 [Certara USA, Inc., Princeton, NJ, USA]. Calculations 
were based on the actual sampling times recorded during 
the study.
The following pharmacokinetic parameters were deter-
mined from the plasma concentration-time data: maximum 
observed concentration (Cmax) following each dose, time to 
maximum observed plasma drug concentration (Tmax) fol-
lowing each dose, area under the curve (AUC) from time 0 
to 24 h (AUC (0–24)) and over each dose interval (AUC (0–7), 
AUC (7–14) and AUC (14–24)), and terminal phase half-life (t½) 
following the third dose (Japanese study only). AUC was cal-
culated using the linear and logarithmic trapezoidal methods 
for increasing and decreasing concentrations, respectively. 
Terminal phase half-life was calculated as ln2/terminal elimi-
nation rate constant (λz).
2.8  Biomarker Assessment
Plasma concentrations of 4β-hydroxycholesterol and choles-
terol were measured by Covance Laboratories (Harrogate, 
UK). Human plasma samples were analysed for cholesterol 
using a validated analytical method based on saponifica-
tion and liquid–liquid extraction, followed by LC–MS/MS 
analysis. LLQ was 500 µg/ml using a 50 µl aliquot of diluted 
human plasma with a HLQ of 5000 µg/ml. Human plasma 
samples were analysed for 4B-hydroxycholesterol using a 
validated analytical method based on liquid–liquid extrac-
tion and derivatization followed by LC–MS/MS analysis. 
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The LLQ was 4 ng/ml using a 25 µl aliquot of human plasma 
with a HLQ of 400 ng/ml.
2.9  Statistical Analysis
Safety and tolerability were summarised for all subjects 
who received at least one dose of study drug (safety popu-
lation). Pharmacokinetic analyses were based on the phar-
macokinetic population, which included all subjects with 
a pharmacokinetic sample analysed. Plasma concentrations 
at each time point were summarised using mean and stand-
ard deviation (SD) and presented in graphical form. AUC, 
Cmax, and t½ were summarised using geometric mean and 
between-subject coefficient of variation (%CVb) around the 
geometric mean pharmacokinetic values. Tmax was summa-
rised using median and range. Post-hoc analyses included 
calculation of ratios for geometric mean AUC and Cmax 
(Japan:Western) and graphical comparisons of AUC and 
Cmax values using box (25th–75th percentiles with median) 
and whisker (10th–90th percentiles) plots at each dose level.
3  Results
3.1  Number of Subjects and Demographics
In Study 1, Part A, 15 healthy subjects were randomised and 
12 (80%) completed the study (Fig. 2). Two subjects (13%) 
were withdrawn because of nonserious AEs (120 mg TID, 
hypertension; 240 mg TID, hematochezia and feces soft). 
At the discretion of the Principal Investigator (PI), one sub-
ject (7%) was withdrawn after the second treatment period 
as their Cmax values at both doses were higher than other 
subjects and for the next single-day 360 mg BID dose were 
predicted to exceed the pharmacokinetic stopping criteria 
of 12.3 µg/dl.
In Part B, 47 subjects were randomised, with 29 (62%) 
completing the study (Fig. 2). Seven subjects (15%) with-
drew because of AEs: one subject receiving placebo (ven-
tricular tachycardia), two subjects in the 120 mg TID group 
(ventricular tachycardia, hordeolum), and four subjects in 
the 240 mg TID group (anxiety, influenza-like illness, mood 
altered, nightmare, pollakiuria, polyuria, and tachycardia). 
Additionally, 11 (23%) subjects were withdrawn at the dis-
cretion of the PI after cardiac events were observed in 6/25 
dosed subjects in Part A, cohort 1, and Part B, cohort 2. 
Consequently, all ten subjects in cohort 2 who had been 
dosed up to that point were withdrawn.
In Study 2, 13 healthy subjects were enrolled and 12 com-
pleted the study. Drug dosing in Period 2 was postponed for 
one subject because of elevated aspartate aminotransferase 
(AST) and alanine transaminase (ALT) on Day 1 of treat-
ment Period 2. The revised study schedule was no longer 
suitable, so the subject was withdrawn at the discretion of 
the PI.
Subject demographics and baseline characteristics for 
both studies are shown in Table 1. For Study 2, subjects 
were, on average, younger (26 years) and weighed less 
Fig. 2  Number of subjects. a 
Western subjects, b Japanese 
subjects. Once an allocation 
number was assigned to a sub-
ject, it was not reassigned to any 
other subject. When a subject 
prematurely discontinued the 
study, replacement subjects 
were recruited and assigned 
to the same sequence as the 
replaced subject
Completed Study (n = 12)
Randomized (n = 15)
• Safety population (n = 15)
• PK population (n = 15)
Withdrawn (n = 3)
Reasons:
Adverse events (n = 2)
Investigator discretion (n = 1)
Part A 
Completed study (n = 29)
Withdrawn (n = 18)
Reasons:
Adverse events ( n = 7)
Investigator discretion (n = 11)
Part B 
Randomized (n = 47)
• Safety population (n = 47)
• PK population (n = 34)
Completed Study (n = 12)
Randomized (n = 13)
• Safety population (n = 13)
• PK population (n = 13)
Withdrawn (n = 1)
Reasons:
Investigator discretion (n=1)
A Study 1 Western Subjects
B Study 2 Japanese Subjects
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(64.0 kg) than subjects from Study 1 (Part A: 45 years, 
78.1 kg; Part B: 40 years, 81.0 kg). Most subjects in Study 
1 were of White/European ancestry (87%), while all subjects 
in Study 2 were Japanese and residing in Japan. Study 1, Part 
A, included five female subjects (33%), while all subjects in 
Part B and Study 2 were male.
3.2  Adverse Events
A summary of AEs that occurred in > 1 subject is presented 
in Supplemental Table 3. Twenty subjects (56%) reported 
AEs in Study 1, Part A, and 38 (81%) reported AEs in Part 
B. Across both parts of Study 1, the most frequently reported 
AE was contact dermatitis [Part A, 9 subjects (25%); Part 
B, 8 (17%)], which was attributed to the electrocardiogram 
and telemetry electrodes. The incidence of AEs was highest 
in the GSK2982772 360 mg BID single-day dosing group 
[7 (78%)], followed by the 120 mg TID group [6 (67%)], 
then the 240 mg TID group [4 subjects (44%)] and the pla-
cebo group [3 subjects (33%)]. In Part B, the incidence of 
AEs was highest in the 240 mg TID repeat dose group [12 
(92%)], followed by the 120 mg TID group [17 (85%)] and 
the placebo group [9 (64%)].
Adverse events of moderate intensity reported in Study 1 
are presented in Supplemental Table 4. In Part B, there was 
one serious AE reported in a male subject who received 
placebo and experienced a mild grade 1 cerebrovascular 
accident on Day 15, 1 day after the last dose.
In Part A, all study drug-related AEs [4 subjects 
(44%)] were of mild intensity. In Part B, one subject in the 
GSK2982772 120 mg TID group developed an asympto-
matic, non-serious elevated ALT [7.5 × the upper limit of 
normal (ULN)] and AST (4.5 × ULN) on Day 15, 1 day after 
the last dose. ALT and AST levels returned to normal within 
4 weeks. The elevated ALT AE was severe in intensity and 
considered related to the study drug due to the absence of 
another plausible explanation. All other study drug-related 
AEs in Part B were mild [2 (10%)] or moderate [2 subjects 
(15%)].
In Parts A and B, six subjects experienced arrhythmia 
events that led to a study pause. Two subjects taking pla-
cebo had atrial tachycardia and four subjects receiving 
GSK2982772 had the appearance of non-sustained ven-
tricular tachycardia (NSVT). All subjects participating in 
the 14-day repeat dose cohorts had extended periods of 
telemetry monitoring on Days 1–4, Day 14, and Day 15 after 
completion of dosing. While the observed cardiac events 
were asymptomatic and not considered medically serious, 
the PI considered the events possibly study drug-related. The 
incidence seemed unexpectedly high in this healthy popula-
tion, and therefore the trial was halted as a precautionary 
measure and further cardiac monitoring implemented. All 
subjects with an arrhythmia event had an echocardiogram 
and follow-up with a 48-h Holter monitor well beyond five 
half-lives of GSK2982772. Following an unblinded evalu-
ation of arrhythmia events, the GSK Sponsor Team and the 
Cardiovascular Safety Panel concluded that the asympto-
matic telemetry abnormalities were unlikely to be related to 
GSK2982772 exposure. The AE profile and safety assess-
ments (vital signs, laboratory values) of all subjects with 
an arrhythmia were reviewed, with no contributory findings 
apparent. Substantial protocol amendments were imple-
mented (baseline 24-h telemetry monitoring and additional 
placebo subjects), and the study was restarted by repeating 
the repeat dose 120 mg TID cohort. After the study restarted, 
there was one additional NSVT event in a placebo subject.
Table 1  Subject demographics and baseline characteristics (safety population)
SD standard deviation, TID three times daily
Demographics Study 1 Study 2 (N = 13)
Part A (N = 15) Part B
Placebo (N = 14) 120 mg TID (N = 20) 240 mg TID (N = 13) Total (N = 47)
Age (years), [mean (SD)] 45.0 (11.6) 39.1 (9.7) 43.3 (10.9) 38.6 (11.0) 40.7 (10.6) 26.2 (7.3)
Sex [n (%)]
 Female 5 (33) 0 0 0 0 0
 Male 10 (67) 14 (100) 20 (100) 13 (100) 47 (100) 13 (100)
Height (cm), [mean (SD)] 173.7 (9.0) 176.6 (6.1) 178.3 (7.6) 175.9 (5.3) 177.1 (6.5) 173.0 (4.0)
Weight (kg), [mean (SD)] 78.1 (14.8) 78.0 (8.2) 85.1 (12.0) 76.2 (12.1) – 64.0 (6.3)
Ancestry [n (%)]
 White/Caucasian/European 13 (87) 12 (86) 19 (95) 10 (77) 41 (87) 0
 African American/African 2 (13) 0 1 (5) 3 (23) 4 (9) 0
 Asian-Japanese 0 1 (7) 0 0 1 (2) 13 (100)
 Asian-East Asian 0 1 (7) 0 0 1 (2) 0
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In Study 2, one subject in the 60 mg TID group (8%) 
experienced a mild ALT increase (84 IU/l; normal range 
5–45 IU/l) and a mild AST increase (100 IU/l; normal range 
10–40 IU/l) during the first 1-day dosing period that was 
reported to be study drug-related (Supplemental Table 5). 
No other AEs were reported in Study 2.
3.3  Pharmacokinetics
3.3.1  Western Subjects
In Study 1, Part A, the shape of the GSK2982772 plasma 
concentration-time profiles was similar across the 120 mg 
and 240 mg TID dose groups (Fig. 3). Cmax tended to be 
higher following the second dose for all BID and TID dos-
ing regimens in Part A (Table 2). For the TID regimens, 
the absorption rate was slower following the third dose, 
with a prolonged Tmax and lower Cmax relative to the first 
and second doses. Cmax and AUC (0–24) values increased 
approximately dose proportionately between the 120 mg 
and 240 mg TID doses, and AUC (0–24) was similar for the 
240 mg TID and 360 mg BID regimens (total dose 720 mg). 
GSK2982772 pharmacokinetic parameters (AUC (0–24), Cmax, 
AUC (0–7)) in the limited number of female participants in 
Study 1 were similar to those observed in healthy males 
(data not shown).
One subject in the 360 mg BID group had a Cmax value 
of 16.0 µg/ml, which exceeded the Cmax stopping criteria 
(12.3 µg/ml). Therefore, no further doses of 360 mg BID 
were administered in Part B.
In Study 1, Part B, the shape of the GSK2982772 plasma 
concentration-time profiles and the derived pharmacokinetic 
parameters were similar to those observed in Part A for the 
120 mg and 240 mg TID regimens. Cmax and AUC (0–24) 
values increased approximately linearly between 120 mg 
TID and 240 mg TID. There was no evidence of accumula-
tion of GSK2982772 following repeat doses of 120 mg TID 
or 240 mg TID based on no appreciable increase in AUC (0–7) 
on Day 14 versus Day 1. GSK2982772 trough concentra-
tions reached steady state by Day 2. Administration of 
GSK2982772 with food (standard or high-fat meal) had no 
apparent effect on the Cmax or AUC compared with the fasted 
state (Table 3).
3.3.2  Japanese Subjects
In Study 2, the shape of the GSK2982772 plasma concentra-
tion-time profiles in Japanese subjects following single-day 
administration of 120 mg TID and 240 mg TID was gener-
ally similar to Western subjects except that a lower Cmax and 
prolonged Tmax for the third dose was observed in Western 
compared with Japanese subjects (Fig. 4). The ratios of the 
geometric means of Cmax and AUC values from the first and 
second dose of GSK2982772 for Japanese:Western subjects 
were close to unity (mean ratios between 0.9 to 1.3) (Table 4) 
indicating that these pharmacokinetic parameters were simi-
lar between the two ethnic groups. The median Tmax after the 
first and second oral dose of 120 mg and 240 mg were also 
similar (Fig. 5; Table 4). However, following the third dose, 
the geometric mean Cmax and AUC (14–24) were approximately 
1.4–1.7 times higher for Japanese subjects than for Western 
subjects (Table 4). AUC (0–24) values were similar in Western 
and Japanese subjects at the same dose levels (120 mg TID 
and 240 mg TID). The inter-individual variability observed 
for Cmax and AUC in Japanese subjects from Study 2 was 
less than that of Western subjects in Study 1 (Tables 2, 4). In 
Japanese subjects, the geometric mean t½, determined after 
the third dose of the TID regimens, was similar for all three 
doses (5.9–7.2 h).
3.4  4β‑Hydroxycholesterol Biomarker
The mean (SD) plasma 4β-hydroxycholesterol-to-
cholesterol ratios on Day 1 and Day 15 were simi-
lar (Day 15 4β-hydroxycholesterol/cholesterol: Day 1 
4β-hydroxycholesterol/cholesterol) [120 mg TID (n = 10), 
1.2 (0.2); 240 mg TID (n = 9), 1.1 (0.3)] indicating that 
14 days of GSK2982772 administration does not substan-
tially change CYP3A4 activity.
4  Discussion
In these studies, the safety, tolerability, and pharmacokinet-
ics of GSK2982772 were evaluated at higher doses (up to 
720 mg/day) than investigated previously (up to 240 mg/
day).
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 120 TID (n=9)
 240 TID (n=9)
Time when dose 
administered
Fig. 3  Plasma GSK2982772 concentration-time profiles (arithmetic 
mean ± SD) for 120 mg TID and 240 mg TID in Western subjects. SD 
standard deviation, TID three times daily
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The GSK2982772 pharmacokinetic characteristics 
of rapid absorption and rapid elimination were as antici-
pated based on the pharmacokinetics previously observed 
[1]. Similar to prior studies at lower dosages, the pharma-
cokinetics of GSK2982772 was approximately dose pro-
portional over the dose range studied (120–240 mg TID), 
indicating no solubility rate-limited absorption or satura-
tion of clearance mechanisms. Additionally, administration 
of GSK2982772 with food (standard or high-fat meal) had 
no apparent impact on pharmacokinetics compared with the 
fasted state, which is similar to previously reported stud-
ies showing only a slight delay in the rate of absorption 
under fed conditions. There was no apparent accumulation 
of GSK2982772 following repeat BID or TID dosing, and 
steady state was reached by Day 2 of repeat dosing.
For the graphical comparisons of GSK2982772 pharma-
cokinetics, the mean concentration-time profiles of Japanese 
subjects following the first and second dose were almost 
superimposable and AUC and Cmax values (120 and 240 mg 
TID) were generally consistent with values in Western sub-
jects. This observation was further supported by post hoc 
analyses of the ratios of the geometric means of Cmax and 
AUC values between Japanese and Western subjects, where 
the ratios generated from the first two doses were close to 
unity.
However, following administration of the third dose, the 
rate of absorption was slower in Western subjects compared 
with Japanese subjects. Differences in absorption may be 
explained by the posture of subjects around the administra-
tion time of the third dose. Japanese subjects were main-
tained in a seated or semi-seated position for 2 h following 
the third dose. While a specific posture was not stipulated for 
Western subjects, the third dose was administered between 
9:00 p.m. and 11:15 p.m., which coincided with bedtime. 
Adopting the recumbent position, which is known to slow 
gastric emptying [9], was more likely in Western sub-
jects and could contribute to the later Tmax and lower Cmax 
observed after the third versus the second dose.
The t1/2 observed in Japanese subjects was consistent with 
that observed following a single oral dose in Western sub-
jects [1].
Currently, an important pathway of GSK2982772 
elimination is considered to be glucuronidation catalysed 
by UGT1A9. Variants of UGT1A9 [10] can contribute to 
variation in pharmacokinetics of UGT1A9 substrates, but 
an association is not always observed [11–17]. While the 
Table 3  Study 1, Part B: GSK2982772 plasma pharmacokinetic parameters in Western subjects (pharmacokinetic population)
%CVb between-subject coefficient of variation around GM, AUC (0–7) area under the plasma concentration-time curve from time 0 to 7 h, Cmax 
maximum plasma concentration, GM geometric mean, TID three times daily




Dosage schedule Fasted Standard meal High-fat meal Fasted Standard meal High-fat meal
Study 1, Part B food effects
 120 mg TID (n = 20) 2.2 (30.0) 2.1 (21.7) 1.8 (29.8) 7.5 (25.5) 7.7 (31.5) 6.9 (24.6)
 240 mg TID (n = 13) 4.4 (45.6) 3.9 (33.8) 4.1 (58.4) 14.8 (45.3) 14.7 (37.6) 16.0 (42.9)
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A 120 mg TID
B 240 mg TID






























Time when dose 
administered
Fig. 4  Plasma GSK2982772 concentration-time profiles (arithmetic 
mean ± SD) in healthy Western and Japanese subjects. a 120 mg TID. 
b 240 mg TID. SD standard deviation, TID three times daily






































































































































































































































































































































































































































































































































































































































































































































































































































































81PK of GSK2982772 in Western and Japanese Subjects
frequencies of UGT1A9 variants with functional conse-
quences can differ between East Asian and European popu-
lations [10], for GSK2982772, the pharmacokinetics were 
similar in the healthy subjects of Japanese and European 
ancestry studied.
There was no increase detected in the mean plasma 
4β-hydroxycholesterol-to-cholesterol ratio following 14 days 
of repeat dose administration, suggesting that GSK2982772 
is not a potent inducer of CYP3A4 up to doses of 240 mg 
TID.
GSK2982772 was well tolerated in healthy subjects. 
The majority of AEs in both studies were mild in intensity. 
Contact dermatitis was the most common AE, consistent 
with previous findings at lower doses of GSK2982772 [1]. 
In Study 1, there was one severe, but non-serious, asymp-
tomatic study drug-related event of transaminase eleva-
tion, which resolved after drug discontinuation. No further 
events occurred in higher dose cohorts. Although an increase 
in NSVT events was observed in Study 1, several factors 
suggest they were unlikely to be related to study medica-
tion. The events occurred at a time beyond elimination of 
the compound (i.e., 5 half-lives) in three of four subjects. 
Furthermore, no significant proportional differences in the 
occurrence rates between active drug and placebo were 
noted, and the incidence of these rhythm variants was not 
different from what is expected in similar healthy popu-
lations [18, 19]. The arrhythmias observed in the healthy 
subjects appeared to be heterogeneous and of diverse mech-
anisms. Some were automatic, some may have been re-
entrant, and none were polymorphous ventricular tachycar-
dia (PMVT). All cases appeared to be monomorphic VT. No 
QT prolongation has been seen in the development program 
to date, and the NSVT events had no corresponding QT pro-
longation. Likewise, there were no associated ST segment 
changes or QRS prolongation. It is unlikely that a single, 
underlying, pro-arrhythmic mechanism with GSK2982772 
exposure exists.
5  Conclusions
The results from the two studies demonstrate that 
GSK2982772 is well tolerated in healthy Japanese and West-
ern subjects up to a daily dose of 720 mg. The pharmacoki-
netics of GSK2982772 was generally similar between Japa-
nese and Western subjects, with differences in parameters 
being partly explained by study differences in dose admin-
istration procedures. Similar safety and pharmacokinetics 
results from these studies support participation of Japanese 
subjects in future global phase studies and the examination 
of GSK2982772 (up to 720 mg daily) as a potential therapy 
for treatment of IMIDs.
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Fig. 5  Comparison of GSK2982772 Cmax, AUC (0–7), and AUC (0–24) 
in healthy Western and Japanese subjects. a Cmax after first dose of 
GSK2982772. b AUC (0–7) after first dose of GSK2982772. c AUC 
(0–24). Boxes represent the 25th–75th percentiles with median shown 
and whiskers represent the 10th–90th percentiles with individual data 
points superimposed. AUC (0–7) area under the plasma concentration-
time curve from time 0 to 7 h, AUC (0–24) area under the plasma con-
centration-time curve from time zero to 24 h, BID twice daily, Cmax 
maximum plasma concentration, TID three times daily
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